In MM, outcomes are poor for patients who are recycled on an anti-CD38 mAb1

hero bg detail - dots
Icon represents percent of patients exposed to anti-CD38 mAb after mAB treatment

>70% exposed to an anti-CD38 by 2L

According to Komodo claims data from 2022, over 30% of patients were exposed to an anti-CD38 mAb-based regimen in 1L, and over 70% of patients were exposed after receiving their 2L treatment2

© September 22, 2023 Komodo Health, Inc. All rights reserved. Reproduction, distribution, transmission, or publication is prohibited. Reprinted with permission.

Icon represents poor outcomes

Poor outcomes once refractory

In MAMMOTH,* a retrospective analysis of 275 patients refractory to an anti-CD38 mAb, 31% of patients refractory to an anti-CD38 mAb responded to their next therapy, with mPFS of 3.4 months and mOS of 9.3 months3

Icon that represents recycling with anti-CD38 mAb

Poor outcomes with recycling

According to a prospective analysis of 32 patients refractory to an anti-CD38 mAb, patients recycled with an anti-CD38 mAb-based regimen in their next line of therapy had an ORR of 0%, mPFS of 1.6 months, and mOS of 10.7 months1

Icon representing important information important blue icon

In a retrospective cohort study of 1118 patients exposed to >1 line of therapy,

nearly half of patients were recycled on an anti-CD38 mAb-based regimen in their next line of therapy4

*Data collected between January 2017 and June 2018. Among the subgroup of 249 patients who received ≥1 subsequent treatment beyond time zero (T0) were analyzed using comparisons of PFS and OS estimates. T0 was the time point when patients met the criteria of progression as defined by the IMWG Response Criteria.

Next steps

Abbreviations: 1L, first line; 2L, second line; IMWG, International Myeloma Working Group; mAb, monoclonal antibody; MM, multiple myeloma; mOS, median overall survival; mPFS, median progression-free survival; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; RRMM, relapsed or refractory multiple myeloma.

References: 1. Mikhael J, Belhadj-Merzoug K, Hulin C, et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021;11(5):89. doi:10.1038/s41408-021-00478-4 2. Data on file. Karyopharm Therapeutics Inc. 2022. 3. Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266-2275. doi:10.1038/s41375-019-0435-7 4. Richter J, Feng Wang P, Molinari A, et al. Treatment patterns and patient outcomes in relapsed/refractory multiple myeloma (RRMM) stratified by exposure to lenalidomide or anti-CD38 therapy and double-class refractory status: a retrospective electronic health record database study. Poster presented at ASH Annual Meeting and Exposition; December 10-13, 2022; New Orleans, Louisiana. 5. Dimopoulos MA, Richardson P, Lonial S. Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022;22(7):460-473. doi:10.1016/j.clml.2022.01.011 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.2.2024. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed November 9, 2023. To view the most recent and complete version of the guideline, go to 7. Revlimid. Prescribing information. Bristol-Myers Squibb; 2023. 8. Velcade. Prescribing information. Takeda Pharmaceuticals; 2022.



XPOVIO® (selinexor) is a prescription medicine approved in combination with bortezomib and dexamethasone (XVd) to treat adult patients with multiple myeloma who have received at least one prior therapy.


Thrombocytopenia: XPOVIO can cause life-threatening thrombocytopenia, potentially leading to hemorrhage. Thrombocytopenia was reported in patients with multiple myeloma.

Thrombocytopenia is the leading cause of dosage modifications. Monitor platelet counts at baseline and throughout treatment. Monitor more frequently during the first 3 months of treatment. Monitor patients for signs and symptoms of bleeding. Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.

Neutropenia: XPOVIO can cause life-threatening neutropenia, potentially increasing the risk of infection.

Monitor more frequently during the first 3 months of treatment. Consider supportive measures, including antimicrobials and growth factors (e.g., G-CSF). Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.

Gastrointestinal Toxicity: XPOVIO can cause severe gastrointestinal toxicities in patients.

Nausea/Vomiting/Diarrhea: Provide prophylactic antiemetics or treatment as needed.

Anorexia/Weight Loss: Monitor weight, nutritional status, and volume status at baseline and throughout treatment and provide nutritional support, fluids, and electrolyte repletion as clinically indicated.

Hyponatremia: XPOVIO can cause severe or life-threatening hyponatremia.

Monitor sodium level at baseline and throughout treatment.

Serious Infection: XPOVIO can cause serious and fatal infections. Atypical infections reported after taking XPOVIO include, but are not limited to, fungal pneumonia and herpesvirus infection.

Neurological Toxicity: XPOVIO can cause life-threatening neurological toxicities.

Coadministration of XPOVIO with other products that cause dizziness or mental status changes may increase the risk of neurological toxicity.

Advise patients to refrain from driving and engaging in hazardous occupations or activities, until the neurological toxicity fully resolves. Institute fall precautions as appropriate.

Embryo-Fetal Toxicity: XPOVIO can cause fetal harm when administered to a pregnant woman.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with a female partner of reproductive potential to use effective contraception during treatment with XPOVIO and for 1 week after the last dose.

Cataracts: New onset or exacerbation of cataract has occurred during treatment with XPOVIO. The incidence of new onset or worsening cataract requiring clinical intervention was reported.


The most common adverse reactions (ARs) (≥20%) in patients with multiple myeloma who received XVd were fatigue, nausea, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract, and vomiting.

Grade 3-4 laboratory abnormalities (≥10%) were thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia and neutropenia.

Fatal ARs occurred in 6% of patients within 30 days of last treatment. Serious ARs occurred in 52% of patients. Treatment discontinuation rate due to ARs was 19%. The most frequent ARs requiring permanent discontinuation in >2% of patients included fatigue, nausea, thrombocytopenia, decreased appetite, peripheral neuropathy and vomiting. Adverse reactions led to XPOVIO dose interruption in 83% of patients and dose reduction in 64% of patients.


No overall difference in effectiveness of XPOVIO was observed in patients >65 years old when compared with younger patients. Patients ≥65 years old had a higher incidence of discontinuation due to an adverse reaction (AR) and a higher incidence of serious ARs than younger patients.

The effect of end-stage renal disease (CLCR <15 mL/min) or hemodialysis on XPOVIO pharmacokinetics is unknown.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Karyopharm Therapeutics Inc. at 1-888-209-9326 or FDA at 1-800-FDA-1088 or

© 2023 Karyopharm Therapeutics Inc.